Jaimie P Meyer1, Javier Cepeda1, Sandra A Springer1, Johnny Wu1, Robert L Trestman1, Frederick L Altice1. 1. Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA (J P Meyer MD, S A Springer MD, Prof F L Altice MD); Chronic Disease Epidemiology (J P Meyer), Epidemiology of Microbial Diseases (J Cepeda MPH, Prof F L Altice), Yale School of Public Health, New Haven, CT, USA; Correctional Managed Healthcare, University of Connecticut, Farmington, CT, USA (J Wu MD, Prof R L Trestman MD); Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA (Prof R L Trestman); and Centre of Excellence on Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia (Prof F L Altice).
Abstract
BACKGROUND: Reincarceration in prison or jail correlates with non-sustained HIV viral suppression, but HIV treatment outcomes in released prisoners who are reincarcerated have not recently been systematically assessed despite advances in antiretroviral treatment (ART) potency, simplicity, and tolerability. METHODS: In a retrospective cohort of reincarcerated inmates with HIV in Connecticut (2005-12), we used longitudinally linked demographic, pharmacy, and laboratory databases to examine correlates of viral suppression. The primary outcome was viral suppression on reincarceration, defined as viral load lower than 400 RNA copies per mL. FINDINGS: Of 497 prisoners and jail detainees with HIV, with 934 reincarcerations, individuals were mostly unmarried, uninsured, and black men prescribed a protease-inhibitor-based ART regimen. During the median 329 days (IQR 179-621) between prison release and reincarceration, the proportion of incarceration periods with viral suppression decreased significantly from 52% to 31% (mean HIV-RNA increased by 0·4 log10; p<0·0001), lower than Connecticut's HIV-infected prison population and those prescribed ART nationally. 158 (51%) of 307 individuals with viral suppression on release had viral suppression on reincarceration. Viral suppression on reincarceration was associated with increasing age (adjusted odds ratio [aOR] 1·04, 95% CI 1·01-1·07), being prescribed non-nucleoside reverse transcriptase inhibitor-based regimens (1·63, 1·14-2·34), and having higher levels of medical or psychiatric comorbidity (1·16, 1·03-1·30). INTERPRETATION: Identification of individuals most at risk for recidivism and loss of viral suppression might mitigate the risk that repeated reincarceration poses to systems of public health and safety. FUNDING: Bristol-Myers Squibb Virology, Patterson Trust, and National Institute on Drug Abuse.
BACKGROUND: Reincarceration in prison or jail correlates with non-sustained HIV viral suppression, but HIV treatment outcomes in released prisoners who are reincarcerated have not recently been systematically assessed despite advances in antiretroviral treatment (ART) potency, simplicity, and tolerability. METHODS: In a retrospective cohort of reincarcerated inmates with HIV in Connecticut (2005-12), we used longitudinally linked demographic, pharmacy, and laboratory databases to examine correlates of viral suppression. The primary outcome was viral suppression on reincarceration, defined as viral load lower than 400 RNA copies per mL. FINDINGS: Of 497 prisoners and jail detainees with HIV, with 934 reincarcerations, individuals were mostly unmarried, uninsured, and black men prescribed a protease-inhibitor-based ART regimen. During the median 329 days (IQR 179-621) between prison release and reincarceration, the proportion of incarceration periods with viral suppression decreased significantly from 52% to 31% (mean HIV-RNA increased by 0·4 log10; p<0·0001), lower than Connecticut's HIV-infected prison population and those prescribed ART nationally. 158 (51%) of 307 individuals with viral suppression on release had viral suppression on reincarceration. Viral suppression on reincarceration was associated with increasing age (adjusted odds ratio [aOR] 1·04, 95% CI 1·01-1·07), being prescribed non-nucleoside reverse transcriptase inhibitor-based regimens (1·63, 1·14-2·34), and having higher levels of medical or psychiatric comorbidity (1·16, 1·03-1·30). INTERPRETATION: Identification of individuals most at risk for recidivism and loss of viral suppression might mitigate the risk that repeated reincarceration poses to systems of public health and safety. FUNDING: Bristol-Myers Squibb Virology, Patterson Trust, and National Institute on Drug Abuse.
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: J D Rich; B P Dickinson; G Macalino; T P Flanigan; C W Towe; A Spaulding; D Vlahov Journal: J Acquir Immune Defic Syndr Date: 1999-10-01 Impact factor: 3.731
Authors: Sandra A Springer; Edward Pesanti; John Hodges; Thomas Macura; Gheorghe Doros; Frederick L Altice Journal: Clin Infect Dis Date: 2004-05-26 Impact factor: 9.079
Authors: Becky L Stephenson; David A Wohl; Rosemary McKaig; Carol E Golin; Lara Shain; Monica Adamian; Cathy Emrick; Ronald P Strauss; Cathie Fogel; Andrew H Kaplan Journal: Int J STD AIDS Date: 2006-02 Impact factor: 1.359
Authors: Jeannia J Fu; Maua Herme; Jeffrey A Wickersham; Alexei Zelenev; Amy Althoff; Nickolas D Zaller; Alexander R Bazazi; Ann K Avery; Jeff Porterfield; Alison O Jordan; Dominique Simon-Levine; Martha Lyman; Frederick L Altice Journal: AIDS Behav Date: 2013-10
Authors: Nitika Pant Pai; Milton Estes; Erica E M Moodie; Arthur L Reingold; Jacqueline P Tulsky Journal: PLoS One Date: 2009-09-22 Impact factor: 3.240
Authors: Bethany L DiPrete; Brian W Pence; Carol E Golin; Kevin Knight; Patrick M Flynn; Jessica Carda-Auten; Jennifer S Groves; Kimberly A Powers; Becky L White; Sonia Napravnik; David A Wohl Journal: AIDS Behav Date: 2019-09
Authors: Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: McKenna C Eastment; Katelynne Gardner Toren; Lara Strick; Susan E Buskin; Matthew R Golden; Julia C Dombrowski Journal: Am J Public Health Date: 2017-03-21 Impact factor: 9.308
Authors: D M Coviello; R Lovato; K Apostol; M M Eisenberg; D S Metzger; R Szucs-Reed; N Kiryankova-Dalseth; D Kelly; A Jackson; M Plano; M B Blank Journal: Community Ment Health J Date: 2018-05-11
Authors: Margaret Erickson; Kate Shannon; Ariel Sernick; Neora Pick; Flo Ranville; Ruth E Martin; Andrea Krüsi Journal: AIDS Date: 2019-01-27 Impact factor: 4.177
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731